A layered cancer-on-a-chip system for anticancer drug screening and disease modeling
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.
Abstract
conditions and more reliable response to the tested drugs. This report presents a new approach to modeling skin cancer (melanoma-on-a-chip) and breast cancer (breast cancer-on-a-chip) using the microfluidic systems. We designed a microfluidic device to co-culture cancer cells with non-malignant cells, which are the main component of the cancer microenvironment. In the construction of the microsystem, we used a scaffold in the form of a porous membrane made of poly(ethylene terephthalate), which enables the regular and reproducible arrangement of cells in the culture and maintains intercellular communication. To demonstrate the functionality of the microsystem, we used it to analyze the effectiveness of photodynamic therapy in the treatment of melanoma and chemotherapy in the treatment of breast cancer. The developed microsystem can be successfully used to model cancer diseases, especially with a layered arrangement of cells in the cancerous tissue, such as melanoma, ductal breast cancer, or breast cancer metastases to the skin.
Overview
CoChat Summary
TL;DR
The paper reports a layered cancer-on-a-chip microfluidic device that co-cultures non-malignant and cancer cells on opposite sides of porous PET membranes to model melanoma and breast cancer. It demonstrates 4-day culture and uses the models to test TPP-based photodynamic therapy and doxorubicin chemotherapy.
Key findings
- The PDMS microsystem with six porous PET membranes supported regular, reproducible double-monolayer co-culture; in representative areas the fibroblast-to-cancer cell ratio was 1:3, and cells formed a 3D layered structure on both membrane surfaces.
- Layered cultures were maintained for at least 4 days; mean cell number increased about 6-fold by day 4 for skin co-culture and more than 6-fold for breast co-culture, though gravity caused cancer cell detachment after 72 h and MCF-7 shape factor and sphericity each increased by 0.51 over two days.
- TPP was non-cytotoxic in the dark from 0–5 µM; after irradiation, viability fell to 44.63 ± 22.57%, 50.89 ± 28.68%, and 29.92 ± 17.94% of control at 1, 3, and 5 µM TPP, respectively.
- Doxorubicin reduced breast co-culture viability to 71.6 ± 22.4% at 0.1 µM, 30.7 ± 2.1% at 10 µM, and 23.9 ± 3.1% at 100 µM; because DOX was introduced through the upper layer, this indicated penetration through fibroblasts and PET pores to cancer cells.
Methods
- Fabrication and culture: two PDMS layers with six porous PET membranes (0.4 µm pores, 2 × 10⁶ pores/cm²); non-malignant cells seeded in upper chambers at 10⁶ cells/mL and 10 µL/min, incubated 24 h, then the device was rotated 180° and cancer cells seeded in lower chambers similarly.
- Models and assays: HaCaT keratinocytes + MeWo cells for melanoma-on-a-chip; HMF fibroblasts + MCF-7 cells for breast cancer-on-a-chip. Viability was measured by AlamarBlue and CAM/PI staining; morphology/sphericity used CellTracker dyes, confocal microscopy, and CellSens software.
- Drug testing and statistics: DOX at 0–100 µM and TPP at 0–15 µM; PDT used LED irradiation (10 min, λ = 640 nm, 40 mW/cm²). Results are mean ± SD from 3 independent experiments with three repetitions, or three independent measurements, analyzed by one-way ANOVA at α = 0.05.
Limitations
- The paper states that further work is needed to add a blood vessel network and immune cells to better reflect the tumor microenvironment.
- Evident from the text: viability in co-culture was assessed without distinguishing non-malignant from cancer cells; only two cancer models/cell-line pairs were tested; gravity caused cancer cell detachment after 72 h; and PDT results showed large standard deviations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 33 Not checked · 62 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The obtained results showed that cells grown in the layered form increased extensively over the four days of culture.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Analysis of cancer-on-a-chip model viability
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The analysis of the obtained results showed that the number of viable fibroblasts and breast cancer cells cultured on the PET membrane scaffold decreased with the increase in the concentration of the tested compound.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Cytotoxicity analysis on a layered breast cancer-on-a-chip model
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the lowest tested concentration of DOX (0.1 µM), breast cell viability was 71.6 % ± 22.4 %.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Cytotoxicity analysis on a layered breast cancer-on-a-chip model
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Studies on optimization of the incubation time of cell coculture in a microsystem with AlamarBlue reagent showed that the maximum fluorescence intensity is emitted by resorufin in metabolically active cells after 45 minutes of incubation (37°C, 5% CO 2 ) (Fig. 4 A).”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Analysis of cancer-on-a-chip model viability
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The analysis of microscopic images of breast cells, seeded in the developed microsystem and stained with CellTrackers showed that both cell lines adhered to both surfaces of the PET membrane.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Data analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 95 claims and every source verdict.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 27
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Analysis of cancer-on-a-chip model viability
“The mean number of cells in the chamber observed on the fourth day increased about 6-fold (compared to the first day of culture) (Fig. 5 A) for skin cells co-culture and more than 6-fold for breast cell co-culture.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Conclusions
“Figure: 5 Fig. 5 Fig. 5 Viability of (A) breast cell co-culture (HMF/MCF-7) and (B) skin cell co-culture (HaCaT/MeWo) in the microsystem determined by the AlamarBlue test (*ANOVA, α=0.05, n≥3).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Cytotoxicity analysis on a layered breast cancer-on-a-chip model
“It equaled 30.7 % ± 2.1 % and 23.9 % ± 3.1 % for concentrations 10 µM and 100 µM, respectively (Fig. 7 A).”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Conclusions
“Figure: 7 Fig. 7 ( Fig. 7 (A) The cells stained with CAM (green-alive cells) and PI (reddead cells) (B) Cell viability after chemotherapy with DOX (*ANOVA, α=0.05, n≥3).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Cytotoxicity analysis on a layered breast cancer-on-a-chip model
“CAM/PI staining for each tested drug concentration is shown in Fig. 7 B.”
§ A layered cancer-on-a-chip system for anticancer drug screening and disease modeling > Conclusions
“Figure: 7 Fig. 7 ( Fig. 7 (A) The cells stained with CAM (green-alive cells) and PI (reddead cells) (B) Cell viability after chemotherapy with DOX (*ANOVA, α=0.05, n≥3).”
Citations
Cites
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Mattiuzzi, C., & Lippi, G. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191008.001 · Cited by 1,491
O’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices
Halldorsson, S., Lucumi, E., Gómez-Sjöberg, R., & Fleming, R. M. T. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.029 · Cited by 1,027
Modelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
Jang, K.-J., Mehr, A. P., Hamilton, G. A., McPartlin, L. A., Chung, S., Suh, K.-Y., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40049b · Cited by 849
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Fundamentals of microfluidic cell culture in controlled microenvironments
Young, E. W. K., & Beebe, D. J. (2010) · Chemical Society Reviews · doi:10.1039/b909900j · Cited by 615
The extracellular matrix in tumor progression and metastasis
Eble, J. A., & Niland, S. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09966-1 · Cited by 613
Research works printed but not linked: 3
- Yang, 2022, Cancer Biol. Med., 19, 319
- Pasman, 2018, J. R. Soc., Interface, 15, 20180351, 10.1098/rsif.2018.0351 · DOI · Paper page
- Lee, 2017, Biomed. Microdevices, 19, 1
Cited by
Organ-on-a-Chip Applications in Microfluidic Platforms
An, L., Liu, Y., & Liu, Y. (2025) · Micromachines · doi:10.3390/mi16020201 · Cited by 79
“MOCs connect single OoCs through pipes or microfluidic channels, usually wrapped in endothelial cells, or provide functional coupling by transferring effluent from the outflow reservoir of one organ to the input reservoir of another organ [133].”
Viegas, J. S. R., & Sarmento, B. F. C. C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115295 · Cited by 36
Organ-on-a-chip: Quo vademus? Applications and regulatory status
Mendes, M., Morais, A. S., Carlos, A., Sousa, J., Pais, A. A. C. C., Mihaila, S. M., & Vitorino, C. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114507 · Cited by 26
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1462293 · Cited by 22
“…Bersini et al., 2014; Chen et al., 2016; Kocal et al., 2016; Khazali et al., 2017; Aleman and Skardal, 2019; Oliver et al., 2020; Hachey et al., 2021; Straehla et al., 2022; Ibrahim et al., 2022; Das et al., 2022; Haque et al., 2022; Flont et al., 2023; Shen et al., 2023; Hachey et al., 2024).”
Pitton, M., Urzì, C., Farè, S., & Negrini, N. C. (2024) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2024.106675 · Cited by 19
Metadata
- Authors
- Flont, M., Dybko, A., & Jastrzębska, E.
- Affiliations
- Warsaw University of Technology (PL)
- Corresponding author
- Jastrzębska, Elżbieta
- Venue
- The Analyst
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2023
- Volume
- 148
- Issue
- 21
- Pages
- 5486-5495
- ISSN
- 0003-2654 (ISSN-L)
- 1364-5528
- OpenAlex
- W4387008785
- Cited by
- 21
- References
- 46
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 9
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-02)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Analyst (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Politechnika Warszawska (1820/2/Z01/POB4/2021)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
- Keywords
- microfluidics, melanoma, breast cancer, co-culture, tumor microenvironment, photodynamic therapy, chemotherapy, anticancer drug screening, disease modeling, metastasis
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Drug Screening Assays, Antitumor, Female, Humans, Melanoma, Models, Biological, Photochemotherapy, Skin Neoplasms, Coculture Techniques, Cell Line, Tumor, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.